Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Endocrine 2Tumor-Agnostic 1Other hematologic neoplasm 1NET 1Head & Neck 1Breast 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Neuroendocrine 1

Interventions

Magnetic Resonance Spectroscopy 15lutetium Lu 177 dotatate 14Specimen Handling 14cabozantinib 10Nivolumab 10pembrolizumab 8Everolimus 8gallium Ga 68 dotatate 7Ipilimumab 6Cisplatin 6Carboplatin 6Etoposide 5trametinib 4olaparib 4lenvatinib 4X-Rays 4Lutetium-177 4Cyclophosphamide 4CTLA-4 Antigen 4fluorodopa F 18 3fludarabine 3dabrafenib 3cemiplimab 3Temozolomide 3Surveys and Questionnaires 3Phantoms, Imaging 3Immunoglobulin G 3Fluorodeoxyglucose F18 3Disulfides 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Positron Emission Tomography Computed Tomography × Endocrine × 90 days × Clear all
NCT06122610 2026-05-15

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

University of Wisconsin, Madison

Phase 1 Recruiting
10 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT06941480 2026-04-14

A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

Memorial Sloan Kettering Cancer Center

Phase 1 Not yet recruiting
12 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡